The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

The Genetics of Soft Tissue Tumors


Mertens gruppbild

Soft tissue tumors (STT) constitute a heterogeneous group of approximately 100 distinct neoplasms, including more than 50 malignant subtypes, so-called sarcomas. Genetic analyses have shown that the clinical and biological variation among these neoplasms is reflected in their genotypes. While the diagnosis of STT has been improved by such genetic biomarkers, the use of genetic information for improved treatment stratification or for developing new treatment targets lags behind. Apart from identifying and implementing new STT biomarkers in the clinic, we pursue three different lines of investigation, aiming at (1) distiguishing patients with low and high, respectively, risks for relapse; (2) evaluating the cellular effects of driver mutations, such as gene fusions; and (3) understanding the genetic mechanisms causing genetic instability and clonal evolution. These questions will be resolved by combining comprehensive genetic analyses with functional studies and thorough clinical correlations. The identification of specific mutations is of immediate clinical importance by providing improved diagnostic precision and opportunities for prognostic evaluation. Furthermore, the results of our studies will shed light on potential new therapeutic targets.  

For publications: or


5 selected publications:

Hofvander J, Jo VY, Fletcher CDM, Puls F, Flucke U, Nilsson J, Magnusson L, Mertens F. PHF1 fusions cause distinct gene expression and chromatin accessibility profiles in ossifying fibromyxoid tumors and mesenchymal cells. Mod Pathol 2020;33:1331-1340.

Puls F, Aigamy A, Flucke U, Menzel T, Sumathi VP, Ploegmakers M, Stoehr R, Kindblom L-G, Hansson M, Sydow S, Arbajian E, Mertens F. Recurrent fusions between YAP1 and KMT2A in morphologically distinct neoplasms within the spectrum of low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma. Am J Surg Pathol 2020;44:594-606.

Al-Ibraheemi A, Folpe AL, Perez-Atayde AR, Perry K, Hofvander J, Arbajian E, Magnusson L, Nilsson J, Mertens F. Aberrant receptor tyrosine kinase signaling in lipofibromatosis: a clinicopathological and molecular genetic study of 20 cases. Mod Pathol 2019;32:423-434.

Hofvander J, Viklund B, Isaksson A, Brosjö O, Vult von Steyern F, Rissler P, Mandahl N, Mertens F. Different patterns of clonal evolution among different sarcoma subtypes followed for up to 25 yearsNat Commun 2018;9:3662.

Arbajian E, Puls F, Antonescu CR, Amary F, Sciot R, Debiec-Rychter M, Järås M, Magnusson L, Nilsson J, Hofvander J, Mertens F. In-depth genetic analysis of sclerosing epithelioid fibrosarcoma reveals recurrent genomic alterations and potential treatment targets. Clin Cancer Res 2017;23:7426-7434.



Fredrik Mertens edited

Fredrik Mertens
Professor, MD, PhD

Department of Laboratory Medicine
Division of Clinical Genetics
Klinikgatan 28
SE-221 84 Lund

Tel: +46 46 222 82 72 
Email: Fredrik [dot] Mertens [at] med [dot] lu [dot] se (Fredrik[dot]Mertens[at]med[dot]lu[dot]se)


Research group members
jakob [dot] hofvander [at] med [dot] lu [dot] se (Jakob Hofvander), PhD student
jan [dot] koster [at] med [dot] lu [dot] se (Jan Köster), PhD student
Linda [dot] Magnusson [at] med [dot] lu [dot] se (Linda Magnusson,) Technician
nils [dot] mandahl [at] med [dot] lu [dot] se (Nils Mandahl,) PhD, professor emeritus
Jenny [dot] Nilsson [at] med [dot] lu [dot] se (Jenny Nilsson), Technician
saskia [dot] sydow [at] med [dot] lu [dot] se (Saskia Sydow), PhD student